Forum Agenda

July 24,13:00-17:40

USTC / China-Japan Pharmaceutical & New Materials Innovation Special Session

Stay tuned

Session Planner: Yonghan Hu, Deputy General Manager & CTO, Evopoint Bio

 

13:00–13:05 Opening Remarks 
Jingyu Li,Founder & CEO,Cellatopia

 

Part I: Antibody & Small Molecule New Drug R&D

 

13:05-13:25 Insights from the Development of GIPR/GLP-1R Bispecific Molecule AMG133: Mechanisms, Applications, and Case Studies of Peptide-Drug Conjugates
Junmin Ye, CSO, Salubris

 

13:25-13:45 Trends and Advances in the Development of Bispecific Antibody–Drug Conjugates with Dual Payloads

Siyi Hu:Vice President, Phrontline Biopharma

 

13:45-14:05 Nanobody Drug Development: Strategies, Case Studies, and Trends
Tengchuan Jin, Professor, USTC Life Sciences and Medicine ; Investigator, State Key Laboratory of Immune Response and Immunotherapy

 

14:05-14:25 mRNA‑mediated precision targeted delivery and protein replacement therapy
Shi Du, Young Distinguished Professor, International College of Innovative Pharmacy, Soochow University

 

14:25-14:45 Developing Bifunctional PROTACs to Address Undruggable Targets
Shaoyun Xiang, Founder & CEO, Polymed

 

14:45-15:05 Remodeling CNS Drug Discovery: A Transformative Era of Central Nervous System Drug R&D
Xuechu Zhen, Professor, College of Pharmaceutical Sciences, Soochow University

 

15:05-15:15 Coffee Break

 

Part II: New Drug Services (Technology Platforms, CDMO, Legal, etc.)

 

15:15-15:35 AI-Driven Cell Therapy and Regenerative Medicine: Current Status, Challenges, and Future Pathways
Jingyu Li,Founder & CEO,Cellatopia

 

15:35-15:55 AI + Quantum Computing: A Swiss Army Knife for Identifying the Next Billion-Dollar GLP Targets
Xiaoran Li,Co-Founder & Chief Executive Officer at OureGenAI

 

15:55-16:15 Building a commercialized process platform for cost reduction and efficiency improvement
Xin Zhuge, Co-founder of Intellective Bio

 

16:15-16:35 3D microphysiological systems: organoid and organ-on-a-chip models for clinical translation
Hongda Sheng, Vice President, Hepabio

 

16:35-16:55 From Project Initiation to Commercial Launch: A Full Landscape of U.S. Litigation Risks for Biopharmaceutical Enterprises

Yingli Wang:Partner,  Ashurst Perkins Coie US LLP

 

16:55-17:35 Panel Discussion:USTC’s Original Innovation – Biopharmaceutical  Innovation and Industry-Academia-Research Translation in the AI Era

Haiyang Wei (Moderator), Vice President,Evopoint Bio
Shaoyun Xiang,Founder & CEO, Polymed
Fred Hu, Deputy General Manager & CTO, Evopoint Biosciences
Junmin Ye, CSO,Shenzhen Salubris Pharmaceuticals Biologics
Siyi Hu, Vice President, Phrontline Biopharma
Tengchuan Jin, Professor at the USTC, and Chief Scientist at Anhui Genebio Biotech.
Frank Hu, Founder, Chairman, and CEO of Starna

 

17:35-17:40 Summary & Closing
Jingyu Li,Founder & CEO,Cellatopia